A Single-Arm, International, Multi-Center Trial of HuMax-CD20, a Fully Human Monoclonal Anti-CD20 Antibody, in Patients With B-Cell Chronic Lymphocytic Leukemia Who Have Failed Fludarabine and Alemtuzumab
Latest Information Update: 04 Jul 2023
At a glance
- Drugs Ofatumumab (Primary)
- Indications Chronic lymphocytic leukaemia
- Focus Registrational; Therapeutic Use
- Sponsors Genmab; GlaxoSmithKline; GSK
- 17 Jun 2011 Actual end date (Mar 2008) added as reported by ClinicalTrials.gov.
- 07 Dec 2010 Final results (n=206) presented at 52nd Annual Meeting and Exposition of the American Society of Hematology
- 09 Aug 2010 Status changed from active, no longer recruiting to completed, according to a GlaxoSmithKline and Genmab media release.